.png){kind=icon}
.png){kind=icon}
Return
Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial
.png){kind=icon}
OA
AI
Z
C
L
P
Y
J
G
X
T
W
X
P
Y
X
Y
Y
X
S
R
S
DOI：10.1016/j.ccell.2026.06.015.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Adding tislelizumab to chemo improves mPR rate in tsMHC-II-positive GC/GEJC patients • Adding tislelizumab to chemo fails to improve mPR or pCR in tsMHC-II-negative patients • tsMHC-II is a PD-L1-independent biomarker for preoperative immunotherapy efficacy
Keywords:
tsMHC-II
perioperative immunotherapy
gastric cancer
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
44.5
Papers:
413
Citations:
5.6W
Organization
No organization information available
Cited Papers